tirzepatide ban Study flags need to monitor frailty risks with GLP-1 drugs for older adults compound tirzepatide ban update π’Important
Description
Fibroid sizes are often compared to fruit sizes
Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population
Compounded GLP-1 drugs are going away Suggested Caption: The shortage of name-brand GLP-1 drugs has ended, and less expensive compounded GLP-1 drugs will no longer be available
Understanding biomarkers, genetic predispositions, and provider-guided titration helps optimize outcomes while minimizing side effects
